Recent advances in aerosol gene delivery systems using non-viral vectors for lung cancer therapy

References

• Mangal S, Gao W, Li T, et al. Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: challenges and opportunities. Acta Pharmacol Sin. 2017;38(6):782–797.
   Google Scholar
• Cheng T-YD, Cramb SM, Baade PD, et al. The international epidemiology of lung cancer: latest trends, disparities, and tumor characteristics. J Thorac Oncol. 2016 oct 01;11(10):1653–1671.
   PubMed Web of Science ®Google Scholar
• Abdelaziz HM, Gaber M, Abd-Elwakil MM, et al. Inhalable particulate drug delivery systems for lung cancer therapy: nanoparticles, microparticles, nanocomposites and nanoaggregates. J Control Release. 2018 Jan;10(269):374–392.
   Web of Science ®Google Scholar
• Didkowska J, Wojciechowska U, Manczuk M, et al. Lung cancer epidemiology: contemporary and future challenges worldwide. Ann Transl Med. 2016 4;Apr(8):150.
   Web of Science ®Google Scholar
• Sundaram S, Trivedi R, Durairaj C, et al. Targeted drug and gene delivery systems for lung cancer therapy. clin cancer res off j am assoc cancer res. 2009 Dec 1;15(23):7299–7308.
   PubMed Web of Science ®Google Scholar
• Goncalves GAR, Paiva RMA. Gene therapy: advances, challenges and perspectives. Einstein (Sao Paulo). 2017 Jul-Sep;15(3):369–375.
   PubMed Web of Science ®Google Scholar
• Hong SH, Park SJ, Lee S, et al. Aerosol gene delivery using viral vectors and cationic carriers for in vivo lung cancer therapy. Expert Opin Drug Deliv. 2015 Jun;12(6):977–991.
   PubMed Web of Science ®Google Scholar
• Lara-Guerra H, Roth JA. Gene therapy for lung cancer. Crit Rev Oncog. 2016;21(1–2):115–124.
   PubMedGoogle Scholar
• Osman N, Kaneko K, Carini V, et al. Carriers for the targeted delivery of aerosolized macromolecules for pulmonary pathologies. Expert Opin Drug Deliv. 2018 Aug;15(8):821–834.
   PubMed Web of Science ®Google Scholar
• Zhang B, Zhang Y, Yu D. Lung cancer gene therapy: transferrin and hyaluronic acid dual ligand-decorated novel lipid carriers for targeted gene delivery. Oncol Rep. 2017 Feb;37(2):937–944.
   PubMed Web of Science ®Google Scholar
• Kim N, Duncan GA, Hanes J, et al. Barriers to inhaled gene therapy of obstructive lung diseases: a review. J Control Release. 2016 Oct;28(240):465–488.
   Web of Science ®Google Scholar
• Zarogouldis P, Karamanos NK, Porpodis K, et al. Vectors for inhaled gene therapy in lung cancer. Int J Mol Sci. 2012;13(9):10828–10862.
   PubMed Web of Science ®Google Scholar
• Alapati D, Morrisey EE. Gene editing and genetic lung disease. Basic research meets therapeutic application. Am J Respir Cell Mol Biol. 2017 Mar;56(3):283–290.
   PubMed Web of Science ®Google Scholar
• Castillo A. Gene editing using CRISPR-Cas9 for the treatment of lung cancer. Colomb Med (Cali). 2016 Dec 30;47(4):178–180.
   PubMed Web of Science ®Google Scholar
• Ginn SL, Amaya AK, Alexander IE, et al. Gene therapy clinical trials worldwide to 2017: an update. J Gene Med. 2018 May;20(5):e3015.
   PubMed Web of Science ®Google Scholar
• Chen C, Yue D, Lei L, et al. Promoter-operating targeted expression of gene therapy in cancer: current stage and prospect. Mol Ther Nucleic Acids. 2018 June 01;11:508–514.
   PubMedGoogle Scholar
• Shao Z, Shao J, Tan B, et al. Targeted lung cancer therapy: preparation and optimization of transferrin-decorated nanostructured lipid carriers as novel nanomedicine for co-delivery of anticancer drugs and DNA. Int J Nanomedicine. 2015;10:1223–1233.
   PubMed Web of Science ®Google Scholar
• Lindsay-Mosher N, Su C. Cancer gene therapy: innovations in therapeutic delivery of CRISPR-Cas9. Drug Discov Today Dis Models. 2016 sep 01;21:17–21.
   Google Scholar
• Wang L, Zheng W, Liu S, et al. Delivery of CRISPR/Cas9 by novel strategies for gene therapy. Chembiochem Eur J Chem Biol. 2019 Mar 1;20(5):634–643.
   PubMed Web of Science ®Google Scholar
• Liu C, Zhang L, Liu H, et al. Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications. J Control Release. 2017 Nov 28;266:17–26.
   PubMed Web of Science ®Google Scholar
• Amreddy N, Babu A, Muralidharan R, et al. Polymeric nanoparticle-mediated gene delivery for lung cancer treatment. Top Curr Chem (Cham). 2017 Apr;375(2):35.
   PubMed Web of Science ®Google Scholar
• Lee HY, Mohammed KA, Nasreen N. Nanoparticle-based targeted gene therapy for lung cancer. Am J Cancer Res. 2016;6(5):1118–1134.
   PubMed Web of Science ®Google Scholar
• Kuzmov A, Minko T. Nanotechnology approaches for inhalation treatment of lung diseases. J Control Release. 2015 Dec;10(219):500–518.
   Web of Science ®Google Scholar
• Loira-Pastoriza C, Todoroff J, Vanbever R. Delivery strategies for sustained drug release in the lungs. Adv Drug Deliv Rev. 2014 Aug;75:81–91.
   PubMed Web of Science ®Google Scholar
• Agu RU, Ugwoke MI, Armand M, et al. The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir Res. 2001;2(4):198–209.
   PubMed Web of Science ®Google Scholar
• Mangal S, Gao W, Li T, et al. Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: challenges and opportunities. Acta Pharmacol Sin. 2017 Jun;38(6):782–797.
   PubMed Web of Science ®Google Scholar
• Feingold KR. Lamellar bodies: the key to cutaneous barrier function. J Invest Dermatol. 2012 Aug;132(8):1951–1953.
   PubMed Web of Science ®Google Scholar
• Mottais A, Le Gall T, Sibiril Y, et al. Enhancement of lung gene delivery after aerosol: a new strategy using non-viral complexes with antibacterial properties. Biosci Rep. 2017 Dec 22;37:6.
   Web of Science ®Google Scholar
• Youngren-Ortiz SR, Gandhi NS, Espana-Serrano L, et al. Aerosol delivery of siRNA to the lungs. Part 1: rationale for gene delivery systems. Kona. 2016 Feb;28(33):63–85.
   Web of Science ®Google Scholar
• Yan Y, Zhou K, Xiong H, et al. Aerosol delivery of stabilized polyester-siRNA nanoparticles to silence gene expression in orthotopic lung tumors. Biomaterials. 2017;118:84–93.
   PubMed Web of Science ®Google Scholar
• Agu RU, Ugwoke MI. In vitro and in vivo testing methods for respiratory drug delivery. Expert Opin Drug Deliv. 2011 Jan;8(1):57–69.
   PubMed Web of Science ®Google Scholar
• Dugernier J, Ehrmann S, Sottiaux T, et al. Aerosol delivery during invasive mechanical ventilation: a systematic review. Crit Care. 2017 Oct 21;21(1):264.
   PubMed Web of Science ®Google Scholar
• Lukashev AN, Zamyatnin AA Jr. Viral vectors for gene therapy: current state and clinical perspectives. Biochem Biokhimiia. 2016 Jul;81(7):700–708.
   PubMed Web of Science ®Google Scholar
• Ramamoorth M, Narvekar A. Non viral vectors in gene therapy – an overview. J clin diagn res. 2015;9(1):GE01–GE6.
   PubMed Web of Science ®Google Scholar
• Xing H, Lu M, Yang T, et al. Structure-function relationships of nonviral gene vectors: lessons from antimicrobial polymers. Acta Biomater. 2019 Mar;1(86):15–40.
   Web of Science ®Google Scholar
• Junquera E, Aicart E. Cationic lipids as transfecting agents of DNA in gene therapy. Curr Top Med Chem. 2014 Mar;14(5):649–663.
   PubMed Web of Science ®Google Scholar
• Alipour S, Montaseri H, Tafaghodi M. Preparation and characterization of biodegradable paclitaxel loaded alginate microparticles for pulmonary delivery. Colloids Surf B Biointerfaces. 2010 Dec 1;81(2):521–529.
   PubMed Web of Science ®Google Scholar
• Kolte A, Patil S, Lesimple P, et al. PEGylated composite nanoparticles of PLGA and polyethylenimine for safe and efficient delivery of pDNA to lungs. Int J Pharm. 2017 May 30;524(1–2):382–396.
   PubMed Web of Science ®Google Scholar
• Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev. 2003 Feb 24;55(3):329–347.
   PubMed Web of Science ®Google Scholar
• Walter E, Dreher D, Kok M, et al. Hydrophilic poly(DL-lactide-co-glycolide) microspheres for the delivery of DNA to human-derived macrophages and dendritic cells. J Control Release. 2001 Sep 11;76(1–2):149–168.
   PubMed Web of Science ®Google Scholar
• Wusiman A, Xu S, Ni H, et al. Immunomodulatory effects of Alhagi honey polysaccharides encapsulated into PLGA nanoparticles. Carbohydr Polym. 2019 May;1(211):217–226.
   Web of Science ®Google Scholar
• Barillet S, Fattal E, Mura S, et al. Immunotoxicity of poly (lactic-co-glycolic acid) nanoparticles: influence of surface properties on dendritic cell activation. Nanotoxicology. 2019;14:1–17.
   PubMedGoogle Scholar
• Okuda T, Morishita M, Mizutani K, et al. Development of spray-freeze-dried siRNA/PEI powder for inhalation with high aerosol performance and strong pulmonary gene silencing activity. J Control Release. 2018 Jun;10(279):99–113.
   Web of Science ®Google Scholar
• Nascimento AV, Singh A, Bousbaa H, et al. Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles. Acta Biomater. 2017 Jan 1;47:71–80.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Zhang M, Liu Y, et al. Reversible covalent cross-linked polycations with enhanced stability and ATP-Responsive behavior for improved siRNA delivery. Biomacromolecules. 2018 Sep 10;19(9):3776–3787.
   PubMed Web of Science ®Google Scholar
• Dalle Vedove E, Costabile G, Merkel OM. Mannose and mannose-6-phosphate receptor-targeted drug delivery systems and their application in cancer therapy. Adv Healthc Mater. 2018. 7. Jul(14):e1701398.
   Web of Science ®Google Scholar
• Norouzi M, Nazari B, Miller DW. Injectable hydrogel-based drug delivery systems for local cancer therapy. Drug Discov Today. 2016 Nov;21(11):1835–1849.
   PubMed Web of Science ®Google Scholar
• Osman G, Rodriguez J, Chan SY, et al. PEGylated enhanced cell penetrating peptide nanoparticles for lung gene therapy. J Control Release. 2018 Sep;10(285):35–45.
   Web of Science ®Google Scholar
• Luo CQ, Jang Y, Xing L, et al. Aerosol delivery of folate-decorated hyperbranched polyspermine complexes to suppress lung tumorigenesis via Akt signaling pathway. Int J Pharm. 2016 Nov 20;513(1–2):591–601.
   PubMed Web of Science ®Google Scholar
• Hong SH, Chang SH, Cho KC, et al. Endoplasmic reticulum-Golgi intermediate compartment protein 3 knockdown suppresses lung cancer through endoplasmic reticulum stress-induced autophagy. Oncotarget. 2016 Oct 4;7(40):65335–65347.
   PubMedGoogle Scholar
• Cho WY, Hong SH, Singh B, et al. Suppression of tumor growth in lung cancer xenograft model mice by poly(sorbitol-co-PEI)-mediated delivery of osteopontin siRNA. Eur J Pharm Biopharm. 2015;94:450–462.
   PubMed Web of Science ®Google Scholar
• Minai-Tehrani A, Jiang HL, Kim YK, et al. Suppression of tumor growth in xenograft model mice by small interfering RNA targeting osteopontin delivery using biocompatible poly(amino ester). Int J Pharm. 2012 Jul 15;431(1–2):197–203.
   PubMed Web of Science ®Google Scholar
• Hong SH, Lee JH, Jiang HL, et al. Dual expression of shAkt1 and Pdcd4 suppresses lung tumorigenesis in K-rasLA1 mice. Anticancer Res. 2015 Apr;35(4):2015–2019.
   PubMed Web of Science ®Google Scholar
• Gankhuyag N, Yu KN, Davaadamdin O, et al. Suppression of tobacco carcinogen-induced lung tumorigenesis by aerosol-delivered glycerol propoxylate triacrylate-spermine copolymer/short hairpin Rab25 RNA complexes in female A/J mice. J Aerosol Med Pulm Drug Deliv. 2017 Apr;30(2):81–90.
   PubMed Web of Science ®Google Scholar
• Kuscu L, Sezer AD. Future prospects for gene delivery systems. Expert Opin Drug Deliv. 2017 Oct;14(10):1205–1215.
   PubMed Web of Science ®Google Scholar
• Rudokas M, Najlah M, Alhnan MA, et al. Liposome delivery systems for inhalation: a critical review highlighting formulation issues and anticancer applications. Med Princ Pract. 2016;25(Suppl 2):60–72.
   PubMed Web of Science ®Google Scholar
• Wu Y, Crawford M, Yu B, et al. MicroRNA delivery by cationic lipoplexes for lung cancer therapy. Mol Pharm. 2011 1;8(4):1381–1389. Aug.
   PubMed Web of Science ®Google Scholar
• Kawakami S, Suzuki S, Yamashita F, et al. Induction of apoptosis in A549 human lung cancer cells by all-trans retinoic acid incorporated in DOTAP/cholesterol liposomes. J Control Release. 2006 Feb 21;110(3):514–521.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Zhu J, Zhou H, et al. Sucrose ester based cationic liposomes as effective non-viral gene vectors for gene delivery. Colloids Surf B Biointerfaces. 2016 Sep;1(145):454–461.
   Web of Science ®Google Scholar
• Zhang D, Wang J, Xu D. Cell-penetrating peptides as noninvasive transmembrane vectors for the development of novel multifunctional drug-delivery systems. J Control Release. 2016 May;10(229):130–139.
   Web of Science ®Google Scholar
• Tagalakis AD, Maeshima R, Yu-Wai-Man C, et al. Peptide and nucleic acid-directed self-assembly of cationic nanovehicles through giant unilamellar vesicle modification: targetable nanocomplexes for in vivo nucleic acid delivery. Acta Biomater. 2017 Mar;15(51):351–362.
   Web of Science ®Google Scholar
• Tesauro D, Accardo A, Diaferia C, et al. Peptide-based drug-delivery systems in biotechnological applications: recent advances and perspectives. Molecules. 2019 Jan 19;24(2):351.
   PubMed Web of Science ®Google Scholar
• Yonenaga N, Kenjo E, Asai T, et al. RGD-based active targeting of novel polycation liposomes bearing siRNA for cancer treatment. J Control Release. 2012 Jun 10;160(2):177–181.
   PubMed Web of Science ®Google Scholar
• Ishiguro S, Alhakamy NA, Uppalapati D, et al. Combined local pulmonary and systemic delivery of AT2R gene by modified TAT peptide nanoparticles attenuates both murine and human lung carcinoma xenografts in mice. J Pharm Sci. 2017 Jan;106(1):385–394.
   PubMed Web of Science ®Google Scholar
• Luther DC, Lee YW, Nagaraj H, et al. Delivery approaches for CRISPR/Cas9 therapeutics in vivo: advances and challenges. Expert Opin Drug Deliv. 2018 Sep;15(9):905–913.
   PubMed Web of Science ®Google Scholar
• Cyranoski D. The CRISPR-baby scandal: what’s next for human gene-editing. Nature. 2019 Feb;566(7745):440–442.
   PubMed Web of Science ®Google Scholar
• Cyranoski D. CRISPR gene-editing tested in a person for the first time. Nature. 2016 Nov 24;539(7630):479.
   PubMed Web of Science ®Google Scholar
• Kim W, Lee S, Kim HS, et al. Targeting mutant KRAS with CRISPR-Cas9 controls tumor growth. Genome res. 2018 Jan11;28(3):374–382.
   Web of Science ®Google Scholar
• Lee W, Lee JH, Jun S, et al. Selective targeting of KRAS oncogenic alleles by CRISPR/Cas9 inhibits proliferation of cancer cells. Sci Rep. 2018 8;8;Aug(1):11879.
   Web of Science ®Google Scholar
• Vojnic M, Kubota D, Kurzatkowski C, et al. Acquired BRAF rearrangements induce secondary resistance to EGFR therapy in EGFR-mutated lung cancers. J Thorac Oncol. 2019 May;14(5):802–815.
   PubMed Web of Science ®Google Scholar
• Vad-Nielsen J, Gammelgaard KR, Daugaard TF, et al. Cause-and-effect relationship between FGFR1 expression and epithelial-mesenchymal transition in EGFR-mutated non-small cell lung cancer cells. Lung Cancer. 2019;132:132–140.
   PubMed Web of Science ®Google Scholar
• Singh S, Trevino J, Bora-Singhal N, et al. EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancer [journal article]. Mol Cancer. 2012 September 25;11(1):73.
   PubMed Web of Science ®Google Scholar
• Tang H, Shrager JB. CRISPR/Cas-mediated genome editing to treat EGFR-mutant lung cancer: a personalized molecular surgical therapy. EMBO Mol Med. 2016 Feb 1;8(2):83–85.
   PubMed Web of Science ®Google Scholar
• Koo T, Yoon AR, Cho HY, et al. Selective disruption of an oncogenic mutant allele by CRISPR/Cas9 induces efficient tumor regression. Nucleic Acids Res. 2017 Jul 27;45(13):7897–7908.
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhou W, Wang X, et al. The CRISPR-Cas9 system: a promising tool for discovering potential approaches to overcome drug resistance in cancer. RSC Adv. 2018;8(58):33464–33472.
   PubMed Web of Science ®Google Scholar
• Chen X, Sun X, Guan J, et al. Rsf-1 influences the sensitivity of non-small cell lung cancer to paclitaxel by regulating NF-kappaB pathway and its downstream proteins. Cell Physiol Biochem. 2017;44(6):2322–2336.
   PubMedGoogle Scholar
• Zhang H, Bahamondez-Canas TF, Zhang Y, et al. PEGylated chitosan for nonviral aerosol and mucosal delivery of the CRISPR/Cas9 system in vitro. Mol Pharm. 2018 Nov 5;15(11):4814–4826.
   PubMed Web of Science ®Google Scholar
• Biagioni A, Laurenzana A, Margheri F, et al. Delivery systems of CRISPR/Cas9-based cancer gene therapy. J Biol Eng. 2018;12:33.
   PubMed Web of Science ®Google Scholar
• He ZY, Men K, Qin Z, et al. Non-viral and viral delivery systems for CRISPR-Cas9 technology in the biomedical field. Sci China Life sci. 2017 May;60(5):458–467.
   PubMed Web of Science ®Google Scholar
• Wang M, Glass ZA, Xu Q. Non-viral delivery of genome-editing nucleases for gene therapy. Gene Ther. 2017 Mar;24(3):144–150.
   PubMed Web of Science ®Google Scholar
• Moreno AM, Fu X, Zhu J, et al. In situ gene therapy via AAV-CRISPR-Cas9-mediated targeted gene regulation. Mol ther. 2018 Jul 5;26(7):1818–1827.
   PubMed Web of Science ®Google Scholar
• Lau CH, Suh Y. In vivo genome editing in animals using AAV-CRISPR system: applications to translational research of human disease. F1000Res. 2017;6:2153.
   PubMedGoogle Scholar
• Fakhiri J, Nickl M, Grimm D. Rapid and simple screening of CRISPR guide RNAs (gRNAs) in cultured cells using adeno-associated viral (AAV) vectors. Methods Mol Biol. 2019;1961:111–126.
   PubMedGoogle Scholar
• Lino CA, Harper JC, Carney JP, et al. Delivering CRISPR: a review of the challenges and approaches. Drug Deliv. 2018 Nov;25(1):1234–1257.
   PubMed Web of Science ®Google Scholar
• Xiao Q, Min T, Ma S, et al. Intracellular generation of single-strand template increases the knock-in efficiency by combining CRISPR/Cas9 with AAV. Mol Genet Genomics. 2018 Aug;293(4):1051–1060.
   PubMed Web of Science ®Google Scholar
• Li L, He ZY, Wei XW, et al. Challenges in CRISPR/CAS9 delivery: potential roles of nonviral vectors. Hum Gene Ther. 2015 Jul;26(7):452–462.
   PubMed Web of Science ®Google Scholar
• Rui Y, Wilson DR, Green JJ. Non-viral delivery to enable genome editing. Trends Biotechnol. 2019 Mar;37(3):281–293.
   PubMed Web of Science ®Google Scholar
• Ryu N, Kim MA, Park D, et al. Effective PEI-mediated delivery of CRISPR-Cas9 complex for targeted gene therapy. Nanomed. 2018 Oct;14(7):2095–2102.
   PubMed Web of Science ®Google Scholar
• Sachdeva M, Sachdeva N, Pal M, et al. CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer. Cancer Gene Ther. 2015 Nov;22(11):509–517.
   PubMed Web of Science ®Google Scholar
• Liu J, Shui SL. Delivery methods for site-specific nucleases: achieving the full potential of therapeutic gene editing. J Control Release. 2016 Dec 28;244(Pt A):83–97.
   PubMed Web of Science ®Google Scholar
• Fukazawa T, Maeda Y, Sladek FM, et al. Development of a cancer-targeted tissue-specific promoter system. Cancer Res. 2004 Jan 1;64(1):363–369.
   PubMed Web of Science ®Google Scholar
• Papadakis ED, Nicklin SA, Baker AH, et al. Promoters and control elements: designing expression cassettes for gene therapy. Curr Gene Ther. 2004 Mar;4(1):89–113.
   PubMed Web of Science ®Google Scholar
• Leao R, Apolonio JD, Lee D, et al. Mechanisms of human telomerase reverse transcriptase (hTERT) regulation: clinical impacts in cancer. J Biomed Sci. 2018 Mar 12;25(1):22.
   PubMed Web of Science ®Google Scholar
• Fukazawa T, Maeda Y, Durbin ML, et al. Pulmonary adenocarcinoma-targeted gene therapy by a cancer- and tissue-specific promoter system. Mol Cancer Ther. 2007 Jan;6(1):244–252.
   PubMed Web of Science ®Google Scholar
• Chao CN, Lin MC, Fang CY, et al. Gene therapy for human lung adenocarcinoma using a suicide gene driven by a lung-specific promoter delivered by JC virus-like particles. PLoS One. 2016;11(6):e0157865.
   PubMed Web of Science ®Google Scholar
• Powell SK, Rivera-Soto R, Gray SJ. Viral expression cassette elements to enhance transgene target specificity and expression in gene therapy. Discov Med. 2015 Jan;19(102):49–57.
   PubMed Web of Science ®Google Scholar
• Swisher SG, Roth JA. p53 Gene therapy for lung cancer. Curr Oncol Rep. 2002 Jul;4(4):334–340.
   PubMedGoogle Scholar
• Garg H, Salcedo R, Trinchieri G, et al. Improved nonviral cancer suicide gene therapy using survivin promoter-driven mutant Bax. Cancer Gene Ther. 2010 Mar;17(3):155–163.
   PubMed Web of Science ®Google Scholar
• Aneja MK, Geiger JP, Himmel A, et al. Targeted gene delivery to the lung. Expert Opin Drug Deliv. 2009 6;Jun(6):567–583.
   Web of Science ®Google Scholar
• Muhamad N, Plengsuriyakarn T, Na-Bangchang K. Application of active targeting nanoparticle delivery system for chemotherapeutic drugs and traditional/herbal medicines in cancer therapy: a systematic review. Int J Nanomedicine. 2018;13:3921–3935.
   PubMed Web of Science ®Google Scholar
• Ayatollahi S, Salmasi Z, Hashemi M, et al. Aptamer-targeted delivery of Bcl-xL shRNA using alkyl modified PAMAM dendrimers into lung cancer cells. Int J Biochem Cell Biol. 2017;92:210–217.
   PubMed Web of Science ®Google Scholar
• Talekar M, Trivedi M, Shah P, et al. Combination wt-p53 and MicroRNA-125b Transfection in a Genetically Engineered Lung Cancer Model Using Dual CD44/EGFR-targeting Nanoparticles. Mol ther. 2016 Apr;24(4):759–769.
   PubMed Web of Science ®Google Scholar
• Zhang M, Kim YK, Cui P, et al. Folate-conjugated polyspermine for lung cancer-targeted gene therapy. Acta Pharm Sin B. 2016 Jul;6(4):336–343.
   PubMed Web of Science ®Google Scholar
• Debien E, Hervouet E, Gautier F, et al. ABT-737 and/or folate reverse the PDGF-induced alterations in the mitochondrial apoptotic pathway in low-grade glioma patients. Clin Epigenetics. 2011;2(2):369–381. 05/15, 02/24/received, 04/10/accepted.
   PubMed Web of Science ®Google Scholar
• Orellana EA, Tenneti S, Rangasamy L, et al. FolamiRs: ligand-targeted, vehicle-free delivery of microRNAs for the treatment of cancer. Sci Transl Med. 2017 Aug 2;9:401.
   Web of Science ®Google Scholar
• Muralidharan R, Babu A, Amreddy N, et al. Tumor-targeted nanoparticle delivery of HuR siRNA inhibits lung tumor growth in vitro and in vivo by disrupting the oncogenic activity of the RNA-binding protein HuR. Mol Cancer Ther. 2017 Aug;16(8):1470–1486.
   PubMed Web of Science ®Google Scholar
• Jiang H, Rivera-Molina Y, Gomez-Manzano C, et al. Oncolytic adenovirus and tumor-targeting immune modulatory therapy improve autologous cancer vaccination. Cancer Res. 2017 Jul 15;77(14):3894–3907.
   PubMed Web of Science ®Google Scholar
• Ganesh S, Iyer AK, Gattacceca F, et al. In vivo biodistribution of siRNA and cisplatin administered using CD44-targeted hyaluronic acid nanoparticles. J Control Release. 2013 Dec 28;172(3):699–706.
   PubMed Web of Science ®Google Scholar
• Leung EL, Fiscus RR, Tung JW, et al. Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. PLoS One. 2010 Nov 19;5(11):e14062.
   PubMed Web of Science ®Google Scholar
• Hao Y, Gao Y, Wu Y, et al. The AIB1siRNA-loaded hyaluronic acid-assembled PEI/heparin/Ca2+ nanocomplex as a novel therapeutic strategy in lung cancer treatment. Int J Mol Med. 2019 Feb;43(2):861–867.
   PubMed Web of Science ®Google Scholar
• Ganesh S, Iyer AK, Weiler J, et al. Combination of siRNA-directed gene silencing with cisplatin reverses drug resistance in human non-small cell lung cancer. Mol Ther Nucleic Acids. 2013 Jul;30(2):e110.
   Google Scholar
• Jin M, Jin G, Kang L, et al. Smart polymeric nanoparticles with pH-responsive and PEG-detachable properties for co-delivering paclitaxel and survivin siRNA to enhance antitumor outcomes. Int J Nanomedicine. 2018;13:2405–2426.
   PubMed Web of Science ®Google Scholar
• Lv T, Li Z, Xu L, et al. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer. Acta Biomater. 2018;76:257–274.
   PubMed Web of Science ®Google Scholar
• Yan Y, Liu L, Xiong H, et al. Functional polyesters enable selective siRNA delivery to lung cancer over matched normal cells. Proc Natl Acad Sci U S A. 2016 Sep 27;113(39):E5702–10.
   PubMed Web of Science ®Google Scholar
• Xin Y, Huang M, Guo WW, et al. Nano-based delivery of RNAi in cancer therapy. Mol Cancer. 2017 Jul 28;16(1):134.
   PubMed Web of Science ®Google Scholar
• LaRocca CJ, Warner SG. Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials. Clin Transl Med. 2018 Nov 14;7(1):35.
   PubMed Web of Science ®Google Scholar
• Ren J, Liu X, Fang C, et al. Multiplex genome editing to generate universal CAR T cells resistant to PD1 Inhibition. clin cancer res off j am assoc cancer res. 2017 May 1;23(9):2255–2266.
   PubMed Web of Science ®Google Scholar